Intelligence Layer

News

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

Hub signal

Search-friendly coverage

Keep the current route structure, but present it with the same premium hierarchy as the homepage.

Explore

Search-friendly hub pages

Regulators

Regulatory Updates

FDA, EMA, PMDA, MHRA, and global regulatory coverage in one crawlable hub.

Trials

Clinical Trial Watch

Phase readouts, trial design updates, enrollment milestones, and study results.

Pipeline

Drug Pipeline

Regulatory pipeline signals, approvals, and market-moving development updates.

Live pharma index

Full coverage

Every signal, indexed and searchable

Browse the complete catalog across approvals, trials, research, devices, and deals - refreshed twice a day.

350+

trusted sources

8k+

indexed stories

2x

daily refresh

Coverage

Latest indexed stories

8,942 stories indexed, page 99 of 150

🌍Sep 9, 2021Industryblueprintgenetics.com

Featured signal

Research collaboration aims to accelerate rare disease diagnostics by combining clinical information, machine learning algorithms, and genetic testing

Publisher

Blueprint Genetics (Quest Diagnostics)

Limited excerpt on-platform. Click anywhere on this card to open the original publisher in a new tab.

Blueprint Genetics (Quest Diagnostics)Original publisher link

Canonical metadata stays public, while full text remains on the original site.

🌍Aug 30, 2021Industryomniab.com

Ligand’s Partner Gloria Biosciences Receives Approval in China for Zimberelimab for the Treatment of Recurrent or Refractory Classical Hodgkin’s Lymphoma

OmniAbOriginal source

🌍Jul 29, 2021Industryguerbet.com

The role of Health Information Technology in the optimization of patient outcomes and data management in modern healthcare organizations

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Reducing the “everyday challenge” of non-target embolization

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Réduire le risque quotidien de l’embolisation non ciblée

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

AI in Life Sciences - Seeing Past the Hype

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

L'IA appliquée aux sciences de la vie : au-delà du phénomène de mode

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

When you join Guerbet, you’ve chosen a human scale, worldwide leader

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

En rejoignant Guerbet, vous choisissez un leader mondial à taille humaine

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Guerbet signe un accord avec icometrix pour la commercialisation exclusive d’icobrain, une solution d’imagerie médicale d’intelligence artificielle, pour l’imagerie cérébrale

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Guerbet and IBM Watson Health announce a second co-development project as part of their strategic partnership for leveraging artificial intelligence in medical imaging | Guerbet

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Guerbet et IBM Watson Health annoncent un deuxième projet de codéveloppement dans le cadre de leur partenariat stratégique alliant l’intelligence artificielle à l’imagerie médicale | Guerbet

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

2018 revenue

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Chiffre d’affaires 2018

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

2019 half-year results

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Résultats semestriels 2019

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Revenue at 30 June 2019

GuerbetOriginal source

🌍Jul 29, 2021Industryguerbet.com

Chiffre d’affaires au 30 juin 2019

GuerbetOriginal source

🌍Jun 3, 2021Industryomniab.com

GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb Licensing Agreement

OmniAbOriginal source

🌍May 25, 2021Industryblueprintgenetics.com

The My Retina Tracker Genetic Testing Program Continues to Expand with Spark Therapeutics Joining as New Collaborator

Blueprint Genetics (Quest Diagnostics)Original source

🇺🇸May 14, 2021Industrydyne-tx.com

FORCE Video - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇺🇸May 8, 2021Industrydyne-tx.com

Finding Strength Beyond Muscle - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇺🇸Apr 26, 2021Industrydyne-tx.com

Perspectives Article - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🌍Apr 13, 2021Industryblueprintgenetics.com

Quest Diagnostics and Blueprint Genetics to Present New Insights from Genetic Testing at the 2021 Annual American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting

Blueprint Genetics (Quest Diagnostics)Original source

🇺🇸Apr 7, 2021Researchcidrap.umn.edu

COVID-19 Scan for Apr 06, 2021

CIDRAPOriginal source

🇨🇦Mar 24, 2021Researchucalgary.ca

Parlez-vous français?

University of CalgaryOriginal source

🇨🇦Mar 18, 2021Researchucalgary.ca

UCalgary Political Science interviews our colleague and Associate Dean, Internationalization and Global Affairs, Dr. Gavin Cameron

University of CalgaryOriginal source

🌍Mar 3, 2021Industrypetros.com

Pop Two — Petro's Chili & Chips™

Petros PharmaceuticalsOriginal source

🌍Mar 2, 2021Industryproqr.com

American Association for Pediatric Ophthalmology (AAPOS) Virtual Meeting

ProQROriginal source

🌍Mar 1, 2021Industrypetros.com

Hint-of-Orange Iced Tea® — Petro's Chili & Chips™

Petros PharmaceuticalsOriginal source

🇬🇧Feb 24, 2021Industryorchard-tx.com

Patient Engagement in the Era of Gene Therapy

Orchard TherapeuticsOriginal source

🌍Feb 17, 2021Industryproqr.com

Expert Perspectives Series - Disease Education and Endpoints in Usher Syndrome

ProQROriginal source

🌍Feb 4, 2021Industryblueprintgenetics.com

New study finds evidence indicating the NRAP gene to be a significant cause of recessive dilated cardiomyopathy

Blueprint Genetics (Quest Diagnostics)Original source

🌍Jan 15, 2021Industrycervomed.com

EIP Pharma Announces Positive Phase 2 Results for Neflamapimod in Mild-to-Moderate Dementia with Lewy bodies (DLB) - CervoMed

CervoMedOriginal source

🌍Jan 15, 2021Industrycervomed.com

EIP Pharma Announces Presentation of Positive Clinical Trial Results with Neflamapimod at the 13th Clinical Trials in Alzheimer’s Disease (CTAD) Meeting - CervoMed

CervoMedOriginal source

🌍Jan 15, 2021Industrycervomed.com

EIP Pharma Announces Publication of Preclinical Results Demonstrating Potential of Neflamapimod to Promote Functional Recovery after Ischemic Stroke - CervoMed

CervoMedOriginal source

🇬🇧Dec 25, 2020Industryorchard-tx.com

Reflecting on the Past Year, Looking Toward New Horizons

Orchard TherapeuticsOriginal source

🇫🇷Dec 24, 2020Researchchu-lyon.fr

Centres de vaccination contre la Covid-19

Hospices Civils de LyonOriginal source

🇬🇧Dec 22, 2020Industryorchard-tx.com

An Open Letter of Gratitude

Orchard TherapeuticsOriginal source

🌍Dec 18, 2020Industryproqr.com

HC Wainwright Virtual BIOCONNECT 2021 Conference

ProQROriginal source

🇨🇦Dec 10, 2020Researchucalgary.ca

Bridging the gap between veterinary and human musculoskeletal health

University of CalgaryOriginal source

🇬🇧Dec 7, 2020Industryorchard-tx.com

My engagement and leadership at Orchard and why it’s important

Orchard TherapeuticsOriginal source

🇨🇦Nov 24, 2020Researchucalgary.ca

Social work researcher to help create national plan to stop violence against women

University of CalgaryOriginal source

🌍Nov 23, 2020Industryomniab.com

Ligand Announces Clinical and Regulatory Progress by Multiple Partners with OmniAb Antibodies

OmniAbOriginal source

🌍Nov 14, 2020Industryproqr.com

3rd Annual Evercore ISI Virtual HealthCONx Conference

ProQROriginal source

🇺🇸Oct 1, 2020Industrydyne-tx.com

Our Focus - Dyne Therapeutics

Dyne TherapeuticsOriginal source

🇬🇧Sep 29, 2020Industryorchard-tx.com

HSC Gene Therapy for Neurological Conditions

Orchard TherapeuticsOriginal source

🌍Sep 10, 2020Industryomniab.com

Ligand Expands OmniAb Antibody Discovery Platform Through the Acquisitions of xCella Biosciences and Taurus Biosciences

OmniAbOriginal source

🌍Sep 4, 2020Industryproqr.com

H.C. Wainwright 22nd Annual Global Investment Conference

ProQROriginal source

🌍Sep 4, 2020Industryproqr.com

Citi's 15th Annual BioPharma Virtual Conference

ProQROriginal source

🌍Sep 4, 2020Industryproqr.com

Chardan Virtual 4th Annual Genetic Medicines Conference

ProQROriginal source

🇬🇧Sep 3, 2020Industryorchard-tx.com

Gene therapy comes in many forms

Orchard TherapeuticsOriginal source

🇺🇸Sep 3, 2020Researchcidrap.umn.edu

News Scan for Sep 02, 2020

CIDRAPOriginal source

🇬🇧Sep 1, 2020Industryorchard-tx.com

Celebrating Orchard’s 5 Year Anniversary

Orchard TherapeuticsOriginal source

🇨🇦Sep 1, 2020Researchucalgary.ca

The 2020 Cy Frank Legacy Lecture

University of CalgaryOriginal source

🌍Aug 25, 2020Industryomniab.com

Ligand OmniAb Partner Immunovant Announced Positive Topline Results from Multicenter, Placebo-Controlled Phase 2a Trial of IMVT-1401 in Myasthenia Gravis

OmniAbOriginal source

🇺🇸Aug 8, 2020Industrynurabio.com

Nura Bio Announces publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS | Nura Bio™

Nura BioOriginal source

🌍Aug 7, 2020Industryomniab.com

CStone Announces That OmniAb-derived CS1001 (Anti-PD-L1) Phase 3 Trial Met the Primary Endpoint as First-Line Treatment in Stage IV Squamous and Non-squamous Non-Small Cell Lung Cancer and Announces Plans to Submit a New Drug Application

OmniAbOriginal source

🇬🇧Jul 24, 2020Industryorchard-tx.com

Next-Generation Gene Therapy Manufacturing: A Key to Long-Term Growth and Sustainability

Orchard TherapeuticsOriginal source

🇧🇪Jul 10, 2020Regulatoryfamhp.be

Coronavirus and the fight led by the FAMHP: the FAMHP carries out hundreds of controls and inspections to ensure the compliance and safety of medicines and health products

FAMHP (Belgium)Original source